Previous IHC studies by Ansari et al. also demonstrated that the high expression of SLC3A2 and SLC7A5 in TNBC, HER2+ and luminal B subtypes was significantly associated with poor patient outcome and shorter survival especially in patients with ER+ breast tumours [186,187]. The gene discussed is ERBB2; the disease is breast neoplasm.